Abstract
Summary
The global ophthalmic drugs market size reached US$ 42.8 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 59.1 Billion by 2028, exhibiting a growth rate (CAGR) of 5.3% during 2023-2028.
Ophthalmic drugs are medications that are specially designed and administered for the treatment of various eye-related disorders, including color blindness, diabetic macular edema, cytomegalovirus (CMV), and age-related macular degeneration (AMD). These medications can be delivered in the form of an emulsion, ointment, aqueous gels, dendrimers, nanosuspensions, or contact lenses. Ophthalmic drugs are manufactured from neomycin, antibiotics, bacitracin, and polymyxin that aid in mitigating the growth of bacterial infection in the eye. At present, they are commercially available in solid, liquid, and semi-solid formulation types.
Ophthalmic Drugs Market Trends:
The increasing prevalence of various eye-related disorders, such as visual impairment, glaucoma, and color blindness, especially amongst the rising geriatric population, is primarily driving the ophthalmic drugs market growth. In line with this, the rising awareness regarding the anti-inflammatory properties of the drug is further facilitating their demand to treat scleritis, cystoid macular edema, and uveitis disorders. Moreover, the extensive fundings and favorable initiatives being undertaken by the governments of several countries to promote the production of effective ophthalmic drugs with novel formulations and combinations are also supporting the market growth. Besides this, significant technological advancements, including the introduction of gene-drug therapies for diagnosing and treating hereditary ophthalmic, neurovascular retinal, and retinoblastoma disorders, are acting as another growth-inducing factors. Additionally, the easy availability of ophthalmic drugs in eye solutions, drops, capsules, tablets, gels, and ointments forms across several online and offline distribution channels is contributing to the market growth. Other factors, such as significant expansion in the pharmaceutical industry, along with rising research and development (R&D) activities to introduce cost-effective ocular drug delivery systems (ODDS), are creating a positive outlook for the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global ophthalmic drugs market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, drug class, indication, dosage form and distribution channel.
Breakup by Type:
Prescription Drugs
Over-the-counter Drugs
Breakup by Drug Class:
Anti-glaucoma
Anti-infection
Anti-inflammation
Anti-allergy
Others
Breakup by Indication:
Dry Eye
Glaucoma
Infection/Inflammation/Allergy
Retinal Disorders
Others
Breakup by Dosage Form:
Liquid Ophthalmic Drug Forms
Solid Ophthalmic Drug Forms
Semisolid Ophthalmic Drug Forms
Multicompartment Drug Delivery Systems
Others
Breakup by Distribution Channel:
Hospital Pharmacies
Drug Stores
Online Pharmacies
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., Aerie Pharmaceuticals Inc., Akorn Inc., Alcon, Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd. and Sun Pharmaceutical Industries Ltd.
Key Questions Answered in This Report:
How has the global ophthalmic drugs market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global ophthalmic drugs market?
What are the key regional markets?
What is the breakup of the market based on the type?
What is the breakup of the market based on the drug class?
What is the breakup of the market based on the indication?
What is the breakup of the market based on the dosage form?
What is the breakup of the market based on the distribution channel?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global ophthalmic drugs market and who are the key players?
What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Ophthalmic Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Type
6.1 Prescription Drugs
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Over-the-counter Drugs
6.2.1 Market Trends
6.2.2 Market Forecast
7 Market Breakup by Drug Class
7.1 Anti-glaucoma
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Anti-infection
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Anti-inflammation
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Anti-allergy
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Others
7.5.1 Market Trends
7.5.2 Market Forecast
8 Market Breakup by Indication
8.1 Dry Eye
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Glaucoma
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Infection/Inflammation/Allergy
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Retinal Disorders
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 Others
8.5.1 Market Trends
8.5.2 Market Forecast
9 Market Breakup by Dosage Form
9.1 Liquid Ophthalmic Drug Forms
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Solid Ophthalmic Drug Forms
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Semisolid Ophthalmic Drug Forms
9.3.1 Market Trends
9.3.2 Market Forecast
9.4 Multicompartment Drug Delivery Systems
9.4.1 Market Trends
9.4.2 Market Forecast
9.5 Others
9.5.1 Market Trends
9.5.2 Market Forecast
10 Market Breakup by Distribution Channel
10.1 Hospital Pharmacies
10.1.1 Market Trends
10.1.2 Market Forecast
10.2 Drug Stores
10.2.1 Market Trends
10.2.2 Market Forecast
10.3 Online Pharmacies
10.3.1 Market Trends
10.3.2 Market Forecast
10.4 Others
10.4.1 Market Trends
10.4.2 Market Forecast
11 Market Breakup by Region
11.1 North America
11.1.1 United States
- 11.1.1.1 Market Trends
- 11.1.1.2 Market Forecast
11.1.2 Canada
- 11.1.2.1 Market Trends
- 11.1.2.2 Market Forecast
11.2 Asia-Pacific
11.2.1 China
- 11.2.1.1 Market Trends
- 11.2.1.2 Market Forecast
11.2.2 Japan
- 11.2.2.1 Market Trends
- 11.2.2.2 Market Forecast
11.2.3 India
- 11.2.3.1 Market Trends
- 11.2.3.2 Market Forecast
11.2.4 South Korea
- 11.2.4.1 Market Trends
- 11.2.4.2 Market Forecast
11.2.5 Australia
- 11.2.5.1 Market Trends
- 11.2.5.2 Market Forecast
11.2.6 Indonesia
- 11.2.6.1 Market Trends
- 11.2.6.2 Market Forecast
11.2.7 Others
- 11.2.7.1 Market Trends
- 11.2.7.2 Market Forecast
11.3 Europe
11.3.1 Germany
- 11.3.1.1 Market Trends
- 11.3.1.2 Market Forecast
11.3.2 France
- 11.3.2.1 Market Trends
- 11.3.2.2 Market Forecast
11.3.3 United Kingdom
- 11.3.3.1 Market Trends
- 11.3.3.2 Market Forecast
11.3.4 Italy
- 11.3.4.1 Market Trends
- 11.3.4.2 Market Forecast
11.3.5 Spain
- 11.3.5.1 Market Trends
- 11.3.5.2 Market Forecast
11.3.6 Russia
- 11.3.6.1 Market Trends
- 11.3.6.2 Market Forecast
11.3.7 Others
- 11.3.7.1 Market Trends
- 11.3.7.2 Market Forecast
11.4 Latin America
11.4.1 Brazil
- 11.4.1.1 Market Trends
- 11.4.1.2 Market Forecast
11.4.2 Mexico
- 11.4.2.1 Market Trends
- 11.4.2.2 Market Forecast
11.4.3 Others
- 11.4.3.1 Market Trends
- 11.4.3.2 Market Forecast
11.5 Middle East and Africa
11.5.1 Market Trends
11.5.2 Market Breakup by Country
11.5.3 Market Forecast
12 SWOT Analysis
12.1 Overview
12.2 Strengths
12.3 Weaknesses
12.4 Opportunities
12.5 Threats
13 Value Chain Analysis
14 Porters Five Forces Analysis
14.1 Overview
14.2 Bargaining Power of Buyers
14.3 Bargaining Power of Suppliers
14.4 Degree of Competition
14.5 Threat of New Entrants
14.6 Threat of Substitutes
15 Price Analysis
16 Competitive Landscape
16.1 Market Structure
16.2 Key Players
16.3 Profiles of Key Players
16.3.1 AbbVie Inc
- 16.3.1.1 Company Overview
- 16.3.1.2 Product Portfolio
- 16.3.1.3 Financials
- 16.3.1.4 SWOT Analysis
16.3.2 Aerie Pharmaceuticals Inc
- 16.3.2.1 Company Overview
- 16.3.2.2 Product Portfolio
- 16.3.2.3 Financials
16.3.3 Akorn Inc
- 16.3.3.1 Company Overview
- 16.3.3.2 Product Portfolio
16.3.4 Alcon
- 16.3.4.1 Company Overview
- 16.3.4.2 Product Portfolio
- 16.3.4.3 Financials
16.3.5 Bausch Health Companies Inc
- 16.3.5.1 Company Overview
- 16.3.5.2 Product Portfolio
16.3.6 Bayer AG
- 16.3.6.1 Company Overview
- 16.3.6.2 Product Portfolio
- 16.3.6.3 Financials
- 16.3.6.4 SWOT Analysis
16.3.7 F. Hoffmann-La Roche AG
- 16.3.7.1 Company Overview
- 16.3.7.2 Product Portfolio
- 16.3.7.3 SWOT Analysis
16.3.8 Johnson & Johnson
- 16.3.8.1 Company Overview
- 16.3.8.2 Product Portfolio
- 16.3.8.3 Financials
- 16.3.8.4 SWOT Analysis
16.3.9 Merck & Co. Inc
- 16.3.9.1 Company Overview
- 16.3.9.2 Product Portfolio
- 16.3.9.3 Financials
- 16.3.9.4 SWOT Analysis
16.3.10 Novartis AG
- 16.3.10.1 Company Overview
- 16.3.10.2 Product Portfolio
- 16.3.10.3 Financials
- 16.3.10.4 SWOT Analysis
16.3.11 Regeneron Pharmaceuticals Inc
- 16.3.11.1 Company Overview
- 16.3.11.2 Product Portfolio
- 16.3.11.3 Financials
- 16.3.11.4 SWOT Analysis
16.3.12 Santen Pharmaceutical Co. Ltd
- 16.3.12.1 Company Overview
- 16.3.12.2 Product Portfolio
16.3.13 Sun Pharmaceutical Industries Ltd
- 16.3.13.1 Company Overview
- 16.3.13.2 Product Portfolio